Combined deficiency of alpha and epsilon sarcoglycan disrupts the cardiac dystrophin complex
Related Experiment Video
Updated: May 29, 2026

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
Published on: August 2, 2018
Alessio Lancioni1, Ida Luisa Rotundo, Yvonne Monique Kobayashi
1Telethon Institute of Genetics and Medicine, Via Pietro Castellino 111, Napoli 80131, Italy.
Insights
Epsilon-sarcoglycan (ε-SG) may prevent heart disease in patients with alpha-sarcoglycan (α-SG) deficiency. Mice lacking both α-SG and ε-SG developed severe cardiomyopathy, suggesting ε-SG
Area of Science:
- Muscle biology
- Genetics
- Cardiology
Background:
- Mutations in sarcoglycan (SG) genes cause skeletal muscle pathology.
- Cardiomyopathy is a rare complication in patients with α-SG gene mutations.
- Epsilon-sarcoglycan (ε-SG) is hypothesized to compensate for α-SG deficiency in the heart.
Purpose of the Study:
- To investigate the function of ε-SG in striated muscle.
- To determine if ε-SG compensates for α-SG deficiency in the heart.
- To understand the role of ε-SG in preventing cardiomyopathy.
Main Methods:
- Generated Sgce-null mice (lacking ε-SG).
- Generated Sgca-;Sgce-null mice (lacking both α-SG and ε-SG).
- Phenotypic analysis of generated mouse models.
Main Results:
- Sgce-null mice exhibited a wild-type phenotype without muscular dystrophy or heart disease.
- Sgca-;Sgce-null mice developed progressive muscular dystrophy and severe cardiomyopathy.
- Sgca-;Sgce-null mice showed a complete loss of residual SGs and reduced dystrophin and dystroglycan.
Conclusions:
- Epsilon-sarcoglycan (ε-SG) plays a crucial role in preventing cardiomyopathy associated with α-SG deficiency.
- ε-SG is important for maintaining cardiac function in the context of α-SG loss.
- This study highlights ε-SG as a potential therapeutic target for certain muscular dystrophies.
Abstract:
Cardiomyopathy is a puzzling complication in addition to skeletal muscle pathology for patients with mutations in β-, γ- or δ-sarcoglycan (SG) genes. Patients with mutations in α-SG rarely have associated cardiomyopathy, or their cardiac pathology is very mild. We hypothesize that a fifth SG, ε-SG, may compensate for α-SG deficiency in the heart. To investigate the function of ε-SG in striated muscle, we generated an Sgce-null mouse and a Sgca-;Sgce-null mouse, which lacks both α- and ε-SGs. While Sgce-null mice showed a wild-type phenotype, with no signs of muscular dystrophy or heart disease, the Sgca-;Sgce-null mouse developed a progressive muscular dystrophy and a more anticipated and severe cardiomyopathy. It shows a complete loss of residual SGs and a strong reduction in both dystrophin and dystroglycan. Our data indicate that ε-SG is important in preventing cardiomyopathy in α-SG deficiency.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Desmosomes
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Satellite Stem Cells and Muscular Dystrophy

